<DOC>
	<DOC>NCT00366327</DOC>
	<brief_summary>An open-label extension study using a variable dose (20 to 30 mg daily) of bifeprunox to evaluate long-term safety.</brief_summary>
	<brief_title>Study Evaluating Bifeprunox in Patients With Schizophrenia.</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>1. Outpatients who have successfully completed Wyeth study 3168A1313. 2. A signed and dated informed consent form for this study. 3. No major protocol violations in the previous study. 1. Clinically important abnormalities in the preceding shortterm study that have not resolved. 2. Use of prohibited treatments in the preceding shortterm study. 3. Meeting any exclusion criteria in the preceding shortterm study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Schizophrenia</keyword>
</DOC>